14 April 2017 : Case report
Mycophenolate Mofetil and Pulmonary Fibrosis After Kidney Transplantation: A Case Report
Unusual or unexpected effect of treatment, Rare disease, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
Kazuhiro Takahashi1ABCDEF*, Pauline Go1ABCDEF, Chad H. Stone2D, Mohamed Safwan1E, Krishna G. Putchakayala1BC, William J. Kane1E, Lauren E. Malinzak1E, Dean Y. Kim1E, Jason E. Denny1ACDEFGDOI: 10.12659/AJCR.902380
Am J Case Rep 2017; 18:399-404
Abstract
BACKGROUND: Mycophenolate mofetil (MMF) induced lung disease has been described in only a few isolated reports. We report a case of fatal respiratory failure associated with MMF after kidney transplantation.
CASE REPORT: A 50-year-old Hispanic male with a history of end-stage renal disease secondary to hypertension underwent deceased donor kidney transplantation. His preoperative evaluations were normal except for a chest x-ray which showed bilateral interstitial opacities. Tacrolimus and MMF were started on the day of surgery. His postoperative course was uneventful and he was discharged on postoperative day 5. One month later, he presented with shortness of breath and a cough with blood-tinged sputum. His respiratory condition deteriorated rapidly, requiring intubation. Chest computer tomography (CT) demonstrated patchy ground-glass opacities with interlobular septal thickening. Comprehensive pulmonary, cardiac, infectious, and immunological evaluations were all negative. Open lung biopsy revealed extensive pulmonary fibrosis with no evidence of infection. He temporarily improved after discontinuation of tacrolimus and MMF, however, on resuming MMF his respiratory status deteriorated again and he subsequently died from hypoxic respiratory failure.
CONCLUSIONS: An awareness of pulmonary lung disease due to MMF is important to prevent adverse outcomes after organ transplantation. MMF must be used with utmost care in recipients with underlying lung disease as their pulmonary condition might make them more susceptible to any harmful effects of MMF.
Keywords: Abnormalities, Drug-Induced, Immunosuppressive Agents, Pulmonary Fibrosis, Tacrolimus
In Press
21 Mar 2024 : Case report
Chlamydia psittaci Pneumonia: Diagnosis, Treatment, and Challenges in the Context of COVID-19Am J Case Rep In Press; DOI: 10.12659/AJCR.942921
22 Mar 2024 : Case report
Sleep Disorders and Traffic Accidents: Unveiling the Hidden RisksAm J Case Rep In Press; DOI: 10.12659/AJCR.943346
24 Mar 2024 : Case report
Uncommon Combination of Hemoglobin Jax and Hemoglobin Constant Spring Leading to Microcytic AnemiaAm J Case Rep In Press; DOI: 10.12659/AJCR.943560
26 Mar 2024 : Case report
Intrabiliary Rupture of a Hepatic Hydatid Cyst: A Case ReportAm J Case Rep In Press; DOI: 10.12659/AJCR.943893
Most Viewed Current Articles
07 Mar 2024 : Case report
Neurocysticercosis Presenting as Migraine in the United StatesDOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
10 Jan 2022 : Case report
A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV...DOI :10.12659/AJCR.935263
Am J Case Rep 2022; 23:e935263
19 Jul 2022 : Case report
Atlantoaxial Subluxation Secondary to SARS-CoV-2 Infection: A Rare Orthopedic Complication from COVID-19DOI :10.12659/AJCR.936128
Am J Case Rep 2022; 23:e936128
23 Feb 2022 : Case report
Penile Necrosis Associated with Local Intravenous Injection of CocaineDOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250